Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions: Effect on ESA requirement

P. G. Bolasco, P. M. Ghezzi, A. Serra, L. Corazza, S. Murtas, M. Mascia, M. Cossu, R. Ferrara, G. Cogoni, F. Cadinu, D. Casu, B. Contu, M. Passaghe, T. Ghisu, M. Ganadu, F. Logias

Research output: Contribution to journalArticle

Abstract

Background: Hemofiltrate reinfusion (HFR) is a form of hemodiafiltration (HDF) in which replacement fluid is constituted by ultrafiltrate from the patient 'regenerated' through a cartridge containing hydrophobic styrene resin. Bicarbonate-based dialysis solutions (DS) used in routine hemodialysis and HDF contain small quantities of acetate (3-5 mM) as a stabilizing agent, one of the major causes of intradialytic hypotension. Acetate-free (AF) DS have recently been made available, substituting acetate with hydrochloric acid. The impact of AF DS during HFR on Hb levels and erythropoietic-stimulating agent (ESA) requirement in chronic dialysis patients was assessed. Patients and Methods: After obtaining informed consent, 30 uremic patients treated by standard bicarbonate dialysis (BHD, DS with acetate) were randomized to treatment in 3-month cycles: first AF HFR, followed by HFR with acetate, and again AF HFR. At the beginning and end of each period, Hb and ESA requirements were evaluated. Results: A significant increase in the Hb level was observed throughout all periods of HFR versus BHD (from 11.1 to 11.86 g/dl; p = 0.04), with a significant decrease of ESA requirements from 29,500 to 25,033 IU/month (p = 0.04). Conclusion: Regardless of the presence or absence of acetate in DS, HFR per se allows a significant lowering of ESA dosage versus BHD, while at the same time increasing Hb levels. Taking for granted the clinical impact produced, HFR seems to provide a relevant decrease in end-stage renal disease patient costs.

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalBlood Purification
Volume31
Issue number4
DOIs
Publication statusPublished - Jun 2011

Keywords

  • Acetate-free dialysis solutions
  • Anemia
  • Erythropoietic-stimulating agent
  • Hemodiafiltration with endogenous reinfusion
  • Hemofiltrate reinfusion

ASJC Scopus subject areas

  • Nephrology
  • Hematology

Fingerprint Dive into the research topics of 'Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions: Effect on ESA requirement'. Together they form a unique fingerprint.

  • Cite this

    Bolasco, P. G., Ghezzi, P. M., Serra, A., Corazza, L., Murtas, S., Mascia, M., Cossu, M., Ferrara, R., Cogoni, G., Cadinu, F., Casu, D., Contu, B., Passaghe, M., Ghisu, T., Ganadu, M., & Logias, F. (2011). Hemodiafiltration with endogenous reinfusion with and without acetate-free dialysis solutions: Effect on ESA requirement. Blood Purification, 31(4), 235-242. https://doi.org/10.1159/000322400